QV Investors Inc. Has $17.47 Million Position in Solventum Co. (NYSE:SOLV)

QV Investors Inc. lifted its holdings in shares of Solventum Co. (NYSE:SOLV) by 59.4% in the third quarter, HoldingsChannel reports. The institutional investor owned 250,562 shares of the company’s stock after buying an additional 93,370 shares during the period. Solventum makes up about 1.5% of QV Investors Inc.’s holdings, making the stock its 26th largest holding. QV Investors Inc.’s holdings in Solventum were worth $17,469,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the stock. National Bank of Canada FI boosted its holdings in shares of Solventum by 4.0% in the 2nd quarter. National Bank of Canada FI now owns 6,093 shares of the company’s stock valued at $314,000 after buying an additional 236 shares during the last quarter. Mather Group LLC. acquired a new stake in Solventum in the third quarter valued at $27,000. Massmutual Trust Co. FSB ADV lifted its stake in Solventum by 64.9% in the third quarter. Massmutual Trust Co. FSB ADV now owns 1,072 shares of the company’s stock valued at $75,000 after acquiring an additional 422 shares during the last quarter. Lwmg LLC grew its position in shares of Solventum by 3.7% in the 3rd quarter. Lwmg LLC now owns 12,401 shares of the company’s stock valued at $865,000 after acquiring an additional 443 shares during the period. Finally, EverSource Wealth Advisors LLC acquired a new position in shares of Solventum during the 1st quarter worth about $30,000.

Solventum Stock Up 0.5 %

Shares of NYSE:SOLV opened at $69.76 on Wednesday. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $96.05. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.31 and a quick ratio of 0.96. The business’s 50-day moving average is $65.28 and its 200-day moving average is $60.86.

Solventum (NYSE:SOLV) last posted its quarterly earnings results on Thursday, August 8th. The company reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.46 by $0.10. The company had revenue of $2.08 billion during the quarter, compared to analyst estimates of $2.05 billion. The business’s revenue for the quarter was up .2% compared to the same quarter last year. On average, research analysts anticipate that Solventum Co. will post 6.38 EPS for the current fiscal year.

Analyst Ratings Changes

SOLV has been the subject of several research analyst reports. Wells Fargo & Company reduced their target price on Solventum from $69.00 to $64.00 and set an “equal weight” rating for the company in a research note on Friday, August 9th. The Goldman Sachs Group lifted their price objective on shares of Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a research report on Monday, August 12th. Bank of America decreased their price objective on shares of Solventum from $70.00 to $60.00 and set a “neutral” rating on the stock in a report on Tuesday, June 25th. Argus initiated coverage on shares of Solventum in a research note on Monday, June 24th. They set a “hold” rating for the company. Finally, Stifel Nicolaus assumed coverage on shares of Solventum in a research note on Tuesday, October 8th. They issued a “buy” rating and a $82.00 price target on the stock. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $64.33.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.